deltatrials

Myelodysplastic syndromes Trials in Clayton, Australia

Conditions / Myelodysplastic syndromes / Clayton, Australia

Myelodysplastic syndromes is a medical condition with active clinical research programs worldwide.

11 total trials for this combination

Showing top 10 of 11 trials

Trials

NCT ID Title Status Phase
NCT04266301 Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) TERMINATED PHASE3
NCT05469737 A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS) ACTIVE_NOT_RECRUITING PHASE2/PHASE3
NCT01928537 Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine COMPLETED PHASE3
NCT05490446 A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS) ACTIVE_NOT_RECRUITING
NCT05168202 A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes TERMINATED PHASE1
NCT04313881 Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) TERMINATED PHASE3
NCT05949684 ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions RECRUITING PHASE3
NCT03682536 A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve ACTIVE_NOT_RECRUITING PHASE3
NCT02281084 Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes COMPLETED PHASE2
NCT04771130 A Study of BGB-11417 in Participants With Myeloid Malignancies RECRUITING

Related Pages